Truist Financial Corp Decreases Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Truist Financial Corp lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,249 shares of the medical equipment provider’s stock after selling 194 shares during the quarter. Truist Financial Corp’s holdings in Lantheus were worth $559,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LNTH. Sanctuary Advisors LLC grew its stake in shares of Lantheus by 58.5% during the 4th quarter. Sanctuary Advisors LLC now owns 18,042 shares of the medical equipment provider’s stock valued at $1,674,000 after purchasing an additional 6,656 shares during the period. State of New Jersey Common Pension Fund D grew its position in Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after buying an additional 115 shares during the period. Rhumbline Advisers increased its holdings in Lantheus by 1.5% during the fourth quarter. Rhumbline Advisers now owns 212,673 shares of the medical equipment provider’s stock valued at $19,026,000 after buying an additional 3,136 shares during the last quarter. Van ECK Associates Corp raised its position in Lantheus by 31.7% in the fourth quarter. Van ECK Associates Corp now owns 76,996 shares of the medical equipment provider’s stock worth $6,888,000 after acquiring an additional 18,524 shares during the period. Finally, MeadowBrook Investment Advisors LLC boosted its stake in shares of Lantheus by 40.1% during the 4th quarter. MeadowBrook Investment Advisors LLC now owns 2,305 shares of the medical equipment provider’s stock worth $206,000 after acquiring an additional 660 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on LNTH. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. Truist Financial upped their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average target price of $132.86.

Lantheus Trading Up 2.5 %

Shares of LNTH opened at $93.82 on Monday. The business’s 50 day moving average is $89.89 and its 200 day moving average is $96.73. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89. The company has a market capitalization of $6.52 billion, a PE ratio of 15.61 and a beta of 0.44.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.